NIVOPOSTOP (GORTEC 2018–01): a phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse - Bourhis, J; Auperin, A; Borel, C (J Clin Oncol, 2025)